selpercatinib


( Last Updated : June 13, 2022)
Generic Name:
selpercatinib
Project Status:
Active
Therapeutic Area:
RET fusion-positive non-small cell lung cancer
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Retevmo
Project Line:
Reimbursement Review
Project Number:
PC0261-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
As monotherapy for the first-line treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). As monotherapy for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and who have received prior systemic therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open19-Jul-21
Call for patient/clinician input closed13-Sep-21
Clarification:

- Patient input submission received from the Canadian Lung Cancer Advocacy Group Breathe Hope, CanCertainty and Lung Cancer Canada

Submission received17-Aug-21
Submission accepted25-Oct-21
Clarification:

- Submission was not accepted for review on 31 Aug 21

Review initiated26-Oct-21
Draft CADTH review report(s) provided to sponsor for comment20-Jan-22
Deadline for sponsors comments31-Jan-22
CADTH review report(s) and responses to comments provided to sponsor25-Feb-22
Expert committee meeting (initial)09-Mar-22
Draft recommendation issued to sponsor22-Mar-22
Draft recommendation posted for stakeholder feedback31-Mar-22
End of feedback period14-Apr-22
Final recommendation issued to sponsor and drug plans28-Apr-22
Final recommendation posted16-May-22
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)12-May-22
CADTH review report(s) posted